The FDA updated the risankizumab label to make pretreatment TB evaluation a matter of clinical judgment across all indications, including psoriasis.
News|Videos|September 18, 2026
Zasocitinib NDA Acceptance: What It Means for Psoriasis Treatment
Author(s)Raj Chovatiya, MD, PhD
Fact checked by: Tim Smith
Raj Chovatiya, MD, PhD, explains where oral TYK2 inhibitor zasocitinib may fit in psoriasis treatment after the FDA accepted its NDA under priority review.
Advertisement
Advertisement
The
Related to this article
Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.
Psoriasis advocates Nitika Chopra and Ayesha Patrick address common misconceptions, how patients can speak up, and simple tips for clinicians.
On World Psoriasis Day, advocates Nitika Chopra and Ayesha Patrick discuss feeling dismissed and what dermatologists should know about skin of color care.
ORKA-001, a half-life extended IL-23p19 antibody, achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B psoriasis trial.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.
Advertisement
Advertisement